VIENNA—Understanding the emerging genomic landscape of breast cancer needed international research including large molecular screening projects—according to Peter Campbell MD PhD, head of Cancer Genetics and Genomics at the Sanger Institute in Cambridge and joint head of the Cancer Genome Project—speaking at the St Gallen Breast Cancer Conference. He gave Oncology Times reporter Sarah Maxwell his insights into how breast cancer genomics can be applied to the clinic.
You may also like...
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer 31 Aug, 2007 Enzalutamide improves overall and progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer 6 Mar, 2014 Chronic Lymphocytic Leukemia After Fludarabine Failure 26 Feb, 2008 Audio Journal of Oncology in Advance – November 15th, 2006 15 Nov, 2006
- Previous story Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
- Next story Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014